Cytokinetics, Incorporated (NASDAQ:CYTK) belongs to Healthcare sector. Its net profit margin is -34.30% and weekly performance is -6.75%. On last trading day company shares ended up $6.08. Cytokinetics, Incorporated (NASDAQ:CYTK) distance from 50-day simple moving average (SMA50) is -3.90%. On 19 June, Cytokinetics (NASDAQ:CYTK) announced that results from three double-blind, randomized, placebo-controlled Phase I studies of CK-2127107 in healthy volunteers were presented in a poster at the 19th International SMA (Spinal Muscular Atrophy) Researcher Meeting held during the 2015 Annual SMA Conference at the Westin Crown Center in Kansas City, MO.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares decreased -5.13% in last trading session and ended the day at $17.19. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced that John (Jack) Weet, Ph.D., has joined the company as its Vice President of Regulatory Affairs and Quality Assurance. Dr. Weet will oversee Collegium’s Regulatory Affairs and Quality Assurance, providing oversight for all U.S. and international filings and interactions with regulatory authorities.
On 09 July, Koss Corporation (NASDAQ:KOSS) shares decreased -1.07% and was closed at $2.32. KOSS EPS growth in last 5 year was -42.14%. Koss Corporation (NASDAQ:KOSS) year to date (YTD) performance is 32.57%.
Diodes Incorporated (NASDAQ:DIOD) ended the last trading day at $22.58. Company weekly volatility is calculated as 3.21% and price to cash ratio as 4.35. Diodes Incorporated (NASDAQ:DIOD) showed a weekly performance of -6.35%. Diodes (NASDAQ:DIOD) was upgraded by Zacks from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Analyst Ratings.Net reports.
Mylan N.V. (NASDAQ:MYL) shares advanced 2.02% in last trading session and ended the day at $70.35. MYL Gross Margin is 46.50% and its return on assets is 5.10%. Mylan N.V. (NASDAQ:MYL) quarterly performance is 0.36%. Mylan N.V. (NASDAQ:MYL) announced the U.S. launch of Bexarotene 75mg Capsules, which is the generic version of Valeant’s Targretin® Capsules. This product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy.